Comparative Pharmacology
Head-to-head clinical analysis: CAPECITABINE versus RASUVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPECITABINE versus RASUVO.
CAPECITABINE vs RASUVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Capecitabine is a prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in the body, which inhibits thymidylate synthase and incorporates into RNA and DNA, leading to cytotoxic effects.
RASUVO is a biosimilar of adalimumab, a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFα) and neutralizes its biological activity by blocking its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecule expression and cytokine release.
Oral, 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period.
Subcutaneous injection: 200 mg once weekly.
None Documented
None Documented
Clinical Note
moderateCapecitabine + Digoxin
"Capecitabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCapecitabine + Digitoxin
"Capecitabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCapecitabine + Deslanoside
"Capecitabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCapecitabine + Acetyldigitoxin
"Capecitabine may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life of capecitabine is approximately 0.75 hours. For its active metabolite 5-fluorouracil, the half-life is about 0.7 hours. Clinically, this short half-life necessitates twice-daily dosing to maintain therapeutic levels.
Approximately 11-17 days (mean 13 days); supports every-4-week dosing interval for methotrexate-naive patients and every-4-week or every-2-week dosing in combination with methotrexate.
Capecitabine is predominantly eliminated renally. Approximately 95.5% of the administered dose is recovered in urine, with 61% as unchanged capecitabine and its metabolites. Fecal excretion accounts for about 2.6%. Biliary elimination is minimal (<1%).
Primarily cleared via proteolysis; renal and fecal excretion of active drug minimal. No specific biliary or renal excretion as a percentage.
Category D/X
Category C
Antimetabolite
Antimetabolite